Logo image of NVOS

NOVO INTEGRATED SCIENCES INC (NVOS) Stock Fundamental Analysis

NASDAQ:NVOS - Nasdaq - US67011T3005 - Common Stock - Currency: USD

0.15  -0.02 (-13.29%)

After market: 0.1132 -0.04 (-24.53%)

Fundamental Rating

1

NVOS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. NVOS may be in some trouble as it scores bad on both profitability and health. NVOS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NVOS has reported negative net income.
NVOS had a negative operating cash flow in the past year.
In the past 5 years NVOS always reported negative net income.
In the past 5 years NVOS always reported negative operating cash flow.
NVOS Yearly Net Income VS EBIT VS OCF VS FCFNVOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of NVOS (-68.87%) is worse than 89.47% of its industry peers.
NVOS's Return On Equity of -244.36% is on the low side compared to the rest of the industry. NVOS is outperformed by 85.09% of its industry peers.
Industry RankSector Rank
ROA -68.87%
ROE -244.36%
ROIC N/A
ROA(3y)-41.58%
ROA(5y)-27.97%
ROE(3y)-70.22%
ROE(5y)-45.76%
ROIC(3y)N/A
ROIC(5y)N/A
NVOS Yearly ROA, ROE, ROICNVOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K -20K -25K

1.3 Margins

With a decent Gross Margin value of 37.68%, NVOS is doing good in the industry, outperforming 67.54% of the companies in the same industry.
In the last couple of years the Gross Margin of NVOS has remained more or less at the same level.
NVOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y0.48%
NVOS Yearly Profit, Operating, Gross MarginsNVOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

1

2. Health

2.1 Basic Checks

NVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NVOS has more shares outstanding
NVOS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NVOS has been reduced compared to a year ago.
NVOS Yearly Shares OutstandingNVOS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
NVOS Yearly Total Debt VS Total AssetsNVOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

NVOS has an Altman-Z score of -4.58. This is a bad value and indicates that NVOS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.58, NVOS is doing worse than 84.21% of the companies in the same industry.
NVOS has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.16, NVOS is doing good in the industry, outperforming 70.18% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z -4.58
ROIC/WACCN/A
WACC7.3%
NVOS Yearly LT Debt VS Equity VS FCFNVOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 0.27 indicates that NVOS may have some problems paying its short term obligations.
NVOS's Current ratio of 0.27 is on the low side compared to the rest of the industry. NVOS is outperformed by 92.98% of its industry peers.
A Quick Ratio of 0.22 indicates that NVOS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.22, NVOS is doing worse than 93.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.27
Quick Ratio 0.22
NVOS Yearly Current Assets VS Current LiabilitesNVOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 84.52% over the past year.
Looking at the last year, NVOS shows a very strong growth in Revenue. The Revenue has grown by 1106.87%.
Measured over the past years, NVOS shows a small growth in Revenue. The Revenue has been growing by 7.18% on average per year.
EPS 1Y (TTM)84.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-635.41%
Revenue 1Y (TTM)1106.87%
Revenue growth 3Y16.95%
Revenue growth 5Y7.18%
Sales Q2Q%-4.2%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVOS Yearly Revenue VS EstimatesNVOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NVOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVOS Price Earnings VS Forward Price EarningsNVOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVOS Per share dataNVOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVO INTEGRATED SCIENCES INC

NASDAQ:NVOS (11/5/2024, 8:00:01 PM)

After market: 0.1132 -0.04 (-24.53%)

0.15

-0.02 (-13.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)07-11 2024-07-11/amc
Earnings (Next)12-11 2024-12-11/amc
Inst Owners5.23%
Inst Owner Change-93.04%
Ins Owners1.14%
Ins Owner Change0%
Market Cap2.86M
Analysts0
Price TargetN/A
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.21
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.71
BVpS0.52
TBVpS-0.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.87%
ROE -244.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.68%
FCFM N/A
ROA(3y)-41.58%
ROA(5y)-27.97%
ROE(3y)-70.22%
ROE(5y)-45.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y0.48%
F-Score3
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.37%
Cap/Sales 0.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.27
Quick Ratio 0.22
Altman-Z -4.58
F-Score3
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)7.85%
Cap/Depr(5y)52.85%
Cap/Sales(3y)1.6%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-635.41%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1106.87%
Revenue growth 3Y16.95%
Revenue growth 5Y7.18%
Sales Q2Q%-4.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.83%
OCF growth 3YN/A
OCF growth 5YN/A